| Document Date: 2009-03-31 14:59:26
Open Document File Size: 2,25 MBShare Result on Facebook
Event Product Issues / / Facility American College of Rheumatology / / IndustryTerm drug product / phage display technology / preservative-free solution / / MedicalCondition severely active psoriatic arthritis / onset rheumatoid arthritis / rheumatoid nodules / disease / total spinal ankylosis / active ankylosing spondylitis / median disease / ankylosing spondylitis / arthritis / AND OTHER OPPORTUNISTIC INFECTIONS / rheumatoid arthritis / asymmetric psoriatic arthritis / severely active rheumatoid arthritis / total ankylosis / severe psoriatic arthritis / diseases / Bath AS disease activity index / human tumor necrosis factor / pathologic inflammation / psoriasis / normal inflammatory and immune responses / total back pain / INVASIVE FUNGAL INFECTIONS / active rheumatoid arthritis / inflammation / I (adalimumab) WARNING RISK OF INFECTIONS TUBERCULOSIS / OF ACTIVE TUBERCULOSIS / psoriatic arthritis / polyarticular arthritis / / Movie In the open / / Organization HUMIRA administration / American College of Rheumatology / / Position Physician / Major / Physician global assessmentC / pH. CLINICAL PHARMACOLOGY General / / Product HUMIRA / sodium chloride / sulfasalazine / mannitol / response / / Technology alpha / Pharmacokinetics / X-ray / antibodies / Pharmacodynamics / recombinant DNA technology / using phage display technology / /
SocialTag |
Page 1 of 37 HUMIRA(I (adalimumab) WARNING